精神障碍候选生物标志物的现状与验证困境
本文综述并批判性评估了孤独症谱系障碍、精神分裂症、焦虑障碍与创伤后应激障碍、重性抑郁与双相障碍、物质使用障碍中最有希望的候选生物标志物,涵盖神经影像、遗传、分子和外周检测。文章指出过去50年大量候选标志物未被证明足够可靠、有效和有用以临床采用,并提出应聚焦少数有希望的候选物进行明确适应症的确定性测试。
要点
- 多数候选生物标志物尚未达到临床可用的可靠性、有效性和实用性标准。
- N170信号、纹状体静息态fMRI指标、ERN等是值得确定性测试的候选物。
- 需在个体水平上具有临床预测性且临床可行,生物标志物才具可操作性。
核心结论
- 精神病学领域缺乏稳健、可靠且有效的生物标志物,绝大多数候选标志物尚未被证明足够可靠、有效和有用以临床采用。
- 应聚焦有限数量的有希望候选物,通过针对特定适应症的确定性测试流程推进。
研究设计与样本
- 本文为综述,回顾并批判性评估了精神病学神经科学文献中针对孤独症谱系障碍、精神分裂症、焦虑障碍与创伤后应激障碍、重性抑郁与双相障碍及物质使用障碍的最有希望候选生物标志物。
主要发现
- 过去50年识别了大量候选生物标志物,但绝大多数未被证明足够可靠、有效和有用以临床采用。
- N170信号可用于孤独症谱系障碍内的亚组识别。
- 纹状体静息态功能磁共振指标如纹状体连接指数(SCI)和功能性纹状体异常(FSA)指数可用于预测精神分裂症的治疗反应。
- 错误相关负波(ERN)可用于预测广泛性焦虑障碍的首次发作,静息态和结构性脑连接组指标可用于预测社交焦虑障碍的治疗反应。
关键数值与推荐
- 候选生物标志物涵盖神经影像、遗传、分子和外周检测,用于确定易感性或疾病存在及预测治疗反应或安全性。
- N170信号、纹状体静息态功能磁共振指标(SCI和FSA指数)、ERN、静息态和结构性脑连接组指标被列为有希望进行确定性测试的候选物。
临床怎么用
- 生物标志物需在个体水平上具有临床预测性且在临床环境中可行,才具有可操作性。
- 可考虑使用移动健康工具在自然环境中在线远程采集选定指标。
- 应为明确界定的目标应用设定具体基准,并建立适当的资金和合作机制。
局限性
- 文章未报告各候选生物标志物的具体效应量、样本量或验证指标数值。
- 文章指出生物标志物验证过程存在关键缺口,多数候选物缺乏足够可靠性、有效性和实用性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The field of psychiatry is hampered by a lack of robust, reliable and valid biomarkers that can aid in objectively diagnosing patients and providing individualized treatment recommendations. Here we review and critically evaluate the evidence for the most promising biomarkers in the psychiatric neuroscience literature for autism spectrum disorder, schizophrenia, anxiety disorders and post-traumatic stress disorder, major depression and bipolar disorder, and substance use disorders. Candidate biomarkers reviewed include various neuroimaging, genetic, molecular and peripheral assays, for the purposes of determining susceptibility or presence of illness, and predicting treatment response or safety. This review highlights a critical gap in the biomarker validation process. An enormous societal investment over the past 50 years has identified numerous candidate biomarkers. However, to date, the overwhelming majority of these measures have not been proven sufficiently reliable, valid and useful to be adopted clinically. It is time to consider whether strategic investments might break this impasse, focusing on a limited number of promising candidates to advance through a process of definitive testing for a specific indication. Some promising candidates for definitive testing include the N170 signal, an event-related brain potential measured using electroencephalography, for subgroup identification within autism spectrum disorder; striatal resting-state functional magnetic resonance imaging (fMRI) measures, such as the striatal connectivity index (SCI) and the functional striatal abnormalities (FSA) index, for prediction of treatment response in schizophrenia; error-related negativity (ERN), an electrophysiological index, for prediction of first onset of generalized anxiety disorder, and resting-state and structural brain connectomic measures for prediction of treatment response in social anxiety disorder. Alternate forms of classification may be useful for conceptualizing and testing potential biomarkers. Collaborative efforts allowing the inclusion of biosystems beyond genetics and neuroimaging are needed, and online remote acquisition of selected measures in a naturalistic setting using mobile health tools may significantly advance the field. Setting specific benchmarks for well-defined target application, along with development of appropriate funding and partnership mechanisms, would also be crucial. Finally, it should never be forgotten that, for a biomarker to be actionable, it will need to be clinically predictive at the individual level and viable in clinical settings.
引用
- Abi-Dargham A, Moeller SJ, Ali F, et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry. 2023. PMID: 37159365. doi:10.1002/wps.21078
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。